Kyoung Eun Lee

Prof. Dr. Kyoung Eun Lee

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
ICIn Jeong Cho
In Jeong Cho
HCHye Jung Chang
Hye Jung Chang
KLKyoung Eun Lee
Kyoung Eun Lee
HWHye Sung Won
Hye Sung Won
MCMoon Young Choi
Moon Young Choi
CSChu-Myong Seong
Chu-Myong Seong
Cho IJ, et al. J Korean Med Sci. 2009 Aug;24(4):747-750. http://dx.doi.org/10.3346/jkms.2009.24.4.747

5 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Soohyeon LeeSoohyeon Lee
Soohyeon Lee
SISeock-Ah Im
Seock-Ah Im
GKGun Min Kim
Gun Min Kim
KJKyung Hae Jung
Kyung Hae Jung
SKSeok Yun Kang
Seok Yun Kang
Yeon Hee 박연희 ParkYeon Hee 박연희 Park
Yeon Hee 박연희 Park
In the era of CDK4/6 inhibitors in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, few trials have been specifically studied to compare quality of life between palbociclib plus endocrine therapy (ET) and cytotoxic chemotherapy exclusively in premenopausal women. We aimed to evaluate differences of patient report outcomes (PROs) between palbociclib plus ET and capecitabine. PROs were assessed using EORTC QLQ-C30 at baseline, every 6 weeks, and the end of treatment. All EORTC QLQ-30 scores were maintained from baseline to the end of treatment. Patients treated palbociclib plus ET arm experienced delay in time-to-deterioration of physical functioning (HR = 0.58, 95% CI, 0.36 to 0.84, p = 0.0058), nausea and vomiting (HR = 0.48; 95% CI, 0.32 to 0.73, p = 0.0005), and diarrhea (HR = 0.42; 95% CI, 0.27 to 0.65, p = 0.001). There was a numeric trend for worsening of insomnia (HR = 1.43; 95% CI, 0.96 to 2.16, p = 0.079) and favoring of appetite loss (HR = 0.69, 95% CI, 0.44 to 1.07, p = 0.09) in the palbociclib plus ET arm. Premenopausal patients with palbociclib plus ET maintained QoL without compromising treatment efficacy.

14 October 2023 in European Journal of Cancer
Verified
Journal Article
Open access
SKSe Hyun Kim
Se Hyun Kim
SISeock-Ah Im
Seock-Ah Im
KSKoung Jin Suh
Koung Jin Suh
KLKyung-Hun Lee
Kyung-Hun Lee
MKMin Hwan Kim
Min Hwan Kim
JKJee Hyun Kim
Jee Hyun Kim
We evaluated the efficacy and safety of nivolumab and eribulin combination therapy for metastatic breast cancer (BC) in Asian populations. In this parallel phase II study, adult patients with histologically confirmed recurrent/metastatic hormone receptor-positive/HER2-negative (HR+HER2-) or triple-negative BC (TNBC) were prospectively enroled from 10 academic hospitals in Korea (ClinicalTrials.gov Identifier: NCT04061863). They received nivolumab (360 mg) on day 1 plus eribulin (1.4 mg/m2) on days 1 and 8 every 3 weeks until disease progression or intolerable toxicity. The primary endpoint was the investigator-assessed 6-month progression-free survival (PFS) rate in each subtype. Secondary endpoints included investigator-assessed objective response rate (ORR) as per Response Evaluation Criteria in Advanced Solid Tumors version 1.1, disease control rate, overall survival, and treatment toxicity. The association between PD-L1 expression and efficacy was investigated. Forty-five patients with HR+HER2- BC and 45 with TNBC were enroled. Their median age was 51 (range, 31-71) years, and 74 (82.2%) received one or two prior treatments before enrolment. Six-month PFS was 47.2% and 25.1% in the HR+HER2- and TNBC cohorts, respectively. Median PFS was 5.6 (95% confidence interval [CI]: 5.3-7.4) and 3.0 (95% CI: 2.1-5.2) months in the HR+HER2- and TNBC groups, respectively. ORRs were 53.3% (complete response [CR]: 0, partial response [PR]: 24) and 28.9% (CR: 1, PR: 12). Patients with PD-L1+ tumours (PD-L1 expression ≥1%) and PD-L1- tumours (ORR 50% versus 53.8% in HR+HER2-, 30.8% versus 29.0% in TNBC) had similar ORRs. Neutropenia was the most common grade 3/4 adverse event; the most common immune-related adverse events (AEs) were grades 1/2 hypothyroidism and pruritus. Five patients discontinued therapy because of immune-related AEs. Nivolumab plus eribulin showed promising efficacy and tolerable safety in previously treated HER2- metastatic BC. NCT04061863.

23 January 2008 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SLSang Min Lee
Sang Min Lee
KLKyoung Eun Lee
Kyoung Eun Lee
HCHye Jung Chang
Hye Jung Chang
MCMoon Young Choi
Moon Young Choi
MCMin-Sun Cho
Min-Sun Cho
KLKyoung Eun Lee
Kyoung Eun Lee

4 September 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
BYBoeun Yoo
Boeun Yoo
AKArang Kim
Arang Kim
HMHye Sung Moon
Hye Sung Moon
MSMin-Kyung So
Min-Kyung So
TJTae-Dong Jeong
Tae-Dong Jeong
Jungwon HuhJungwon Huh
Jungwon Huh
Boeun Yoo, M.S., Arang Kim, M.S., Hye Sung Moon, M.S., Min-Kyung So, M.D., Ph.D., Tae-Dong Jeong, M.D., Ph.D., Kyoung Eun Lee, M.D., Ph.D., Byung-In Moon, M.D., Ph.D., and Jungwon Huh, M.D., Ph.D.. Ann Lab Med 2024;44:82-91. https://doi.org/10.3343/alm.2024.44.1.82

1 January 2014 in Tumori Journal
Verified
Journal Article
Open access
HWHye Sung Won
Hye Sung Won
KLKyoung Eun Lee
Kyoung Eun Lee
SSSun Hee Sung
Sun Hee Sung
MCMoon Young Choi
Moon Young Choi
JJJung Youn Jo
Jung Youn Jo
KLKyoung Eun Lee
Kyoung Eun Lee
The aims of this study were to investigate the correlation between topoisomerase II alpha (TOP2A), microtubule-associated protein-tau (MAPtau) and other prognostic factors in breast cancer and to evaluate the predictive value of TOP2A and MAP-tau in breast cancer patients who received anthracycline and taxane-containing adjuvant chemotherapy. Seventy patients with axillary lymph node positive breast cancer who underwent curative surgery between January 2000 and December 2005 were evaluated retrospectively. The levels of protein expression of TOP2A and MAPtau were assessed using immunohistochemistry. Among the 70 patients, 43 (61.4%) showed TOP2A overexpression and 30 (42.9%) showed MAP-tau positivity. TOP2A overexpression was associated with p53 positivity and high histological grade. MAP-tau positivity was associated with a lower positive lymph node ratio, lower proliferative activity, and hormone receptor positivity. Based on the TOP2A and MAP-tau expression, there was no significant difference in disease-free survival in the breast cancer patients who received anthracycline and taxane-containing adjuvant chemotherapy. We conclude that immunohistochemical analysis of TOP2A and MAPtau protein expression may not predict the benefits of adjuvant anthracycline and taxane chemotherapy in axillary node positive breast cancer.